Can nicotine pouches help adults stop smoking?

What does the trial evidence show?

Randomized evidence remains limited. A 2025 systematic review in Addiction identified seven trials involving 269 adults. The studies examined outcomes including product satisfaction, urges to smoke and cigarette consumption, used different pouch strengths and comparators, and were generally small. Across those trials, none demonstrated a statistically significant increase in smoking cessation compared with control conditions, snus or nicotine gum.

One pilot trial reported a decline in daily cigarette consumption over eight weeks among adults assigned 4 mg pouches. That is a potentially useful signal, but it does not establish sustained abstinence. A person can smoke fewer cigarettes while remaining exposed to combustible smoke, and a result from one small study may not persist in a larger or longer trial.

Why are craving reduction, cigarette reduction and cessation different outcomes?

A product may temporarily reduce an urge to smoke without helping someone stop permanently. It may also reduce the number of cigarettes smoked while creating stable dual use. Clinical cessation research therefore places greater weight on sustained, preferably biochemically verified abstinence at meaningful follow-up than on immediate liking or short-term cigarette counts.

The distinction matters because nicotine pouches are convenient to use where smoking is not. That can support a transition away from cigarettes, but it can also extend nicotine use across more of the day without eliminating smoking. Studies must report complete switching, partial reduction, dual use and relapse separately before a reliable cessation conclusion can be drawn.

What did the two recent systematic reviews conclude?

Two 2025 systematic reviews reached a similar high-level conclusion: the evidence is not yet sufficient to show that oral nicotine pouches help people stop smoking. The Addiction review included seven randomized trials with 269 adult participants. It found that pouches were sometimes rated more favourably than gum or placebo for satisfaction, but less favourably than cigarettes, and that none of the included studies demonstrated a statistically significant increase in cessation.

The Cochrane review used a prespecified search and eligibility process and assessed cessation, adverse events, biomarkers and population outcomes. It judged much of the available evidence to be low or very low certainty because the studies were few, small, imprecise and at risk of bias. Its conclusion was not that pouches cannot help any individual; it was that current trials do not provide reliable evidence of benefit or harm for cessation at the level needed for a confident general claim.

These reviews overlap but are not interchangeable. They used somewhat different eligibility decisions and outcome frameworks. Agreement between them strengthens the description of the evidence gap, but it does not create a larger underlying trial population. The same small studies remain beneath much of the synthesis.

How do nicotine pouches compare with established cessation treatments?

Established nicotine-replacement medicines are designed, labelled and evaluated for smoking cessation. Depending on jurisdiction, these include patches, gum and lozenges, alongside prescription and non-nicotine options. Their evidence base spans many more trials and longer clinical experience than the evidence available for modern consumer nicotine pouches.

The comparison is not simply “nicotine versus nicotine.” Medicines use defined dosing instructions, contraindications and treatment claims within a regulated therapeutic framework. Consumer pouches vary widely in strength and formulation and may be marketed for enjoyment or convenience rather than a structured reduction in dependence. That difference affects both evidence and behaviour.

The FDA advises that approved cessation products can help and that combining medication with behavioural support improves the chance of quitting. This report does not select a treatment for an individual. Medical history, pregnancy, age, dependence and previous quit attempts can all affect what is appropriate, which is why a qualified clinician or recognised cessation service is the right source for personal guidance.

What are the main limitations in the evidence?

Sample size is the first limitation. Across the Addiction review, individual studies included only 24 to 63 participants. Small studies can detect strong immediate effects but are poorly suited to estimating sustained abstinence or uncommon adverse outcomes. Their results are also more vulnerable to chance and imbalance between groups.

Duration is the second. Short follow-up can measure liking, nicotine exposure, withdrawal symptoms and cigarette counts; it cannot establish durable cessation. Product heterogeneity adds another problem: strengths, flavours, formulations and instructions differ, so pooling results may conceal meaningful differences or imply a category effect that no single trial tested.

Finally, many studies were not designed primarily as cessation trials. A laboratory comparison of pharmacokinetics or satisfaction can inform whether a product might substitute for a cigarette, but it does not answer whether people quit. The research question, participant intent and outcome must align before the result is described as cessation evidence.

What evidence would justify a stronger answer?

A stronger conclusion would require adequately powered randomized trials in adults who smoke and intend to quit. Trials should identify every product and dose, use sustained and biochemically verified abstinence as a primary outcome, record dual use and continued pouch use, and follow participants for at least six months. Comparisons with established treatment and with behavioural support would be more informative than comparison with no active help alone.

Independent replication and transparent funding are important because manufacturers have direct access to products and commercial incentives. Industry-funded evidence should not be discarded automatically, but protocols, outcomes, attrition and analysis decisions must be visible. Publication of unfavourable results is essential to prevent an exaggerated record.

Population evidence would add another layer: whether wider pouch availability is followed by complete switching, continued dual use, youth initiation or changes in smoking prevalence. Such studies cannot replace randomized trials for individual efficacy, but they can show whether a product promoted as an alternative produces the intended pattern at scale.